CXD101

Generic Name: CXD101

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₉N_₅O

CAS Number: 934828-12-3

Unique Ingredient Identifier: 5TNV87ICD2

Background: CXD101 is under investigation in clinical trial NCT03873025 (A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-cell Lymphoma).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Phase 1 Trial of CXD101 in Patients With Advanced Cancer

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: CXD101

First Posted Date: 2013-11-07

Last Posted Date: 2022-10-18

Lead Sponsor: Oxford University Hospitals NHS Trust

Target Recruit Count: 51

Registration Number: NCT01977638

Locations: 🇬🇧
Oxford University Hospitals NHS Trust, Oxford, Oxfordshire, United Kingdom

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy